Health Care · Laboratory Analytical Instruments · Nasdaq · CIK 1110803 · FYE Jan 3 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $205.09Day +5.27%Mkt cap $31.0BP/E (FY) 37.6×1Y +92.3%Off 52W high −0.2%Vol (1Y) 48.3%
Daily closing price, split-adjusted to the current basis; 3y shown of 6,536 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest5.8% of sh out |
| Days to cover4.4d |
| 13F net flow (QoQ)−1.89% |
| Top-10 13F concentration47.6% |
| Next report (est.)2026-10-29 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)37.6× |
| Sales (TTM)$4.49B |
| Earnings (TTM)$825.0M |
| ROE33.4% |
| Net margin19.6% |
| Sales growth 3Y−1.8% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+56.4% |
| 1Y+92.3% |
| 3Y+9.7% |
| 5Y−57.5% |
| 10Y+23.5% |
| Since incept. (ann.)+9.6% |
Total return through 2026-07-30 · series begins 2000-07-28. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)48.3% |
| Ann. volatility (3Y)44.2% |
| Sharpe (1Y)1.56 |
| Sharpe (3Y)0.29 |
| Max drawdown (1Y)−25.7% |
| Max drawdown (3Y)−62.4% |
| Beta (3Y vs SPY)1.40 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 19.0M | $2.3B | 12.44% | +3.8% |
| Capital World Investors | 15.5M | $1.9B | 10.17% | −22.6% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 6.8M | $841M | 4.46% | new |
| VANGUARD CAPITAL MANAGEMENT LLC | 6.6M | $813M | 4.31% | new |
| STATE STREET CORP | 6.4M | $792M | 4.20% | +3.9% |
| WCM INVESTMENT MANAGEMENT, LLC | 5.9M | $716M | 3.87% | +45.5% |
| AQR CAPITAL MANAGEMENT LLC | 4.0M | $491M | 2.60% | −10.1% |
| Corvex Management LP | 3.8M | $472M | 2.50% | +0.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. Institutional 13F holdings sum to 102.2% of shares outstanding. Readings above 100% reflect securities-lending double counting: shares on loan to short sellers are reported long by both the lending institution and the one that bought them. FINRA short interest of 6,546,522 shares (settlement 2026-04-30) accounts for the excess.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-06-28 | 2026-07-30 | $1.35 | −9.4% | $1.16B | +9.4% |
| 2026-03-29 | 2026-04-30 | $0.87 | +6.1% | $1.09B | +4.8% |
| 2025-12-28 | 2026-02-05 | — | — | $1.16B | +5.0% |
| 2025-09-28 | 2025-10-30 | $0.98 | −77.8% | $1.08B | +0.4% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-10-29 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Sequencing 92% · Microarray 8%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
